Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 91 publications
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 14, 2026
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 13, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
Journal: The Lancet. Haematology
Published: September 18, 2025
Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 14, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
Journal: British journal of haematology
Published: May 27, 2025
Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia.
Journal: British journal of haematology
Published: April 19, 2025
Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Haematopoietic Stem Cell Transplantation for Relapsed/Refractory Large B-cell Lymphoma.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: March 28, 2025
Last Updated: 09/26/2026